BACKGROUND: Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC. METHODS: Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin's concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism. RESULTS: Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (pâ<â0.001 and pâ<â0.05, respectively), while resistin mRNA levels were lower (pâ<â0.001). Negative association existed among plasma resistin and HDL-C concentrations (Ïâ=â-â0.280; pâ<â0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUCâ=â0.898). We found no associations of rs1862513 with the examined markers. CONCLUSIONS: Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin's secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.
Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine.
结直肠癌患者中抵抗素、腺苷酸环化酶相关蛋白 1 和高密度脂蛋白胆固醇之间的关联:多标志物方法,是创新预测、预防和个性化医疗的标志
阅读:5
作者:Mihajlovic Marija, Ninic Ana, Sopic Miron, Miljkovic Milica, Stefanovic Aleksandra, Vekic Jelena, Spasojevic-Kalimanovska Vesna, Zeljkovic Dejan, Trifunovic Bratislav, Stjepanovic Zeljka, Zeljkovic Aleksandra
| 期刊: | Epma Journal | 影响因子: | 5.900 |
| 时间: | 2019 | 起止号: | 2019 Jul 20; 10(3):307-316 |
| doi: | 10.1007/s13167-019-00178-x | 研究方向: | 肿瘤 |
| 疾病类型: | 肠癌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
